Keyphrases
Morphine
87%
Postoperative Pain
51%
Repeated Time-to-event
47%
Gabapentin
47%
Pharmacokinetics
36%
Exposure-response
31%
Opioid Consumption
31%
AMPA Receptor (AMPAR)
31%
High Dose
31%
Naloxone
31%
Hydroxybutyrate
31%
Time-to-event Modeling
30%
Pharmacodynamic Interactions
30%
Population Pharmacokinetics
26%
Model-based Approach
21%
Analgesic
21%
Experimental Pain
19%
Depolarization
19%
Clinical Development Programs
19%
Receptor Antagonist
19%
Ca(II)
18%
Clinical Trials
18%
Glucuronide
18%
Time-to-event Analysis
18%
Plasma Concentration
17%
Clinical Development
17%
Human Pain Model
16%
Ketone Bodies
16%
GABAergic Neurons
15%
Latent Sensitization
15%
Obese Adolescents
15%
Induced Toxicity
15%
Molecular Pharmacology
15%
Stereostructure
15%
Amino
15%
Neocortical Neurons
15%
Simulation Analysis
15%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
15%
Activity Relationship
15%
GABAB Receptor
15%
Fixed-dose Combination
15%
Aglycemia
15%
Compound Action Potential
15%
Voltage-gated Calcium Channels
15%
Analgesia
15%
Pain Intensity
15%
Dose Exposure
15%
5-aminovaleric Acid
15%
Glutaric
15%
Glutaconic Acid
15%
Pharmacology, Toxicology and Pharmaceutical Science
Morphine
100%
Pharmacokinetic
64%
Pharmacodynamics
61%
Gabapentin
47%
Postoperative Pain
39%
Receptor
33%
Clinical Trial
32%
Hydroxybutyric Acid
31%
Naloxone
31%
Combination Drug
31%
Aspartic Acid
27%
Pharmacokinetic Modeling
23%
Glucuronide
18%
Glutamic Acid
17%
Experimental Pain
16%
Ketone Body
16%
4 Aminobutyric Acid Receptor
15%
5 Aminovaleric Acid
15%
Molecular Pharmacology
15%
4 Aminobutyric Acid
15%
Acidemia
15%
Neurotoxicity
15%
Midazolam
15%
Drug Development
15%
Morphine 6 Glucuronide
15%
Ultra High Performance Liquid Chromatography
15%
Alpha Amino 3 Hydroxy 5 Methyl 4 Isoxazolepropionic Acid
15%
Rat Model
15%
Propionic Acid
15%
Adenosine Triphosphate Sensitive Potassium Channel
15%
Carbon 13
15%
